The independent source for health policy research, polling, and news.
How Full FDA Approval Could Spur Vaccination
In this Axios column, Drew Altman says full FDA approval of COVID-19 vaccines can provide a big boost to vaccination efforts if treated as an opportunity for updated messaging from government officials at all levels and public health experts and new actions from employers.
Column Read PostThe Health System Appears To Be Selling LGBT+ People Short
With much focus on equity in the nation’s health care system during the pandemic, Drew Altman’s Axios column brings attention to warning signs about health care provided to LGBT+ individuals.
Column Read PostThe Sleeper Health Cost Policy
In this Axios column, Drew Altman unpacks President Biden’s recent executive order on promoting competition, exploring its significance for new efforts to control health costs by addressing consolidation in the health care industry.
Column Read PostWhy Drug Price Negotiation Has Staying Power
In this Axios column, Drew Altman looks beyond Medicare to what’s at stake for employers and workers in the debate about the government negotiating drug prices.
Column Read PostExpanding Medicare to Adults at Age 60 Years—Medicare-for-More?
In this column for the JAMA Health Forum, Larry Levitt examines the implications of lowering Medicare’s age of eligibility, which is emerging as a potential pathway toward Medicare-for-all or a public option among single-payer advocates. He explores the implications for costs, industry, people and broader reform efforts.
Column Read PostPersistent Vaccine Myths
With news that the country has now vaccinated half of its population with at least one dose, This Drew Altman Axios column highlights the persistent COVID-19 vaccine myths that are believed by a substantial portion of the unvaccinated population and discusses the options to address vaccine misinformation.
Column Read Post